New Market Access and Health Policy Research Has Been Reported by Researchers at Health Economics Unit (Cost-effectiveness of infant hypoallergenic formulas to manage cow’s milk protein allergy in France): Health and Medicine – Market Access and Health Policy

Health & Medicine Daily

2023 DEC 13 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Daily -- New study results on market access and health policy have been published. According to news reporting out of the Health Economics Unit by NewsRx editors, research stated, “ABSTRACTBackground Clinician’s choice of hypoallergenic formulas in the first-line management of cow’s milk protein allergy (CMPA) should be informed by evidence on clinical efficacy and cost-effectiveness. We compare the cost-effectiveness of amino acid-based formula (AAF), extensively hydrolyzed casein formula with Lactobacillus rhamnosus Gorbach Goldin (EHCF+LGG), extensively hydrolyzed whey formula (EHWF), and rice hydrolyzed formula (RHF) in non-breastfed children in France.”

Funders for this research include Reckitt Benckiser Health France Mead Johnson Nutrition, UK Reckitt Benckiser.

The news correspondents obtained a quote from the research from Health Economics Unit: “Immunotolerance and atopic manifestations’ prevalence were based on a prospective non-randomized study with a 36-month follow-up. Resource utilization was sourced from a survey of French clinicians, and unit costs were based on national data. Costs and health consequences were discounted at 2.5% annually. Results were reported using the Collective and French National Health Insurance perspectives. Children receiving EHCF+LGG were predicted to require less healthcare resources, given their reduced prevalence of CMPA symptoms at 3 years. In the base case, EHCF+LGG led to savings of at least €674 per child compared to AAF, EHWF, and RHF at 3 years, from both perspectives. Nutrition had the highest economic burden in CMPA, driven by hypoallergenic formulas and dietetic replacements costs. Results were robust to one-way and probabilistic sensitivity analyses.”

According to the news reporters, the research concluded: “EHCF+LGG was associated with more symptom-free time, higher immune tolerance, and lower costs.”

For more information on this research see: Cost-effectiveness of infant hypoallergenic formulas to manage cow’s milk protein allergy in France. Journal of Market Access & Health Policy, 2023,11(1). (Journal of Market Access & Health Policy - http://www.tandfonline.com/toc/zjma20/current). The publisher for Journal of Market Access & Health Policy is Taylor & Francis Group.

A free version of this journal article is available at https://doi.org/10.1080/20016689.2022.2154418.

Our news editors report that more information may be obtained by contacting Ana Teresa Paquete, Health Economics Unit, Health Economics Consultants, Global Market Access Solutions, St-Prex, Switzerland. Additional authors for this research include Rui Martins, Mark P. Connolly, Marie Meulle, Nitida Pastor, Gregoire Benoist, Patrick Tounian.